Sitagliptin

Bezeichnung:Sitagliptin

CAS-Nr486460-32-6

Englisch Name:Sitagliptin

CBNumberCB01449778

SummenformelC16H15F6N5O

Molgewicht407.31

MOL-Datei486460-32-6.mol

Sitagliptin physikalisch-chemischer Eigenschaften

Schmelzpunkt	114.1-115.7 °C
Siedepunkt	529.9±60.0 °C(Predicted)
Dichte	1.61±0.1 g/cm3(Predicted)
storage temp.	Store at -20°C
Löslichkeit	DMSO : ≥ 50 mg/mL (122.76 mM)
Aggregatzustand	Solid
pka	7.20±0.10(Predicted)
Farbe	White to off-white
InChI	InChI=1S/C16H15F6N5O/c17-10-6-12(19)11(18)4-8(10)3-9(23)5-14(28)26-1-2-27-13(7-26)24-25-15(27)16(20,21)22/h4,6,9H,1-3,5,7,23H2/t9-/m1/s1
InChIKey	MFFMDFFZMYYVKS-SECBINFHSA-N
SMILES	C(N1CCN2C(C(F)(F)F)=NN=C2C1)(=O)C[C@H](N)CC1=CC(F)=C(F)C=C1F
CAS Datenbank	486460-32-6(CAS DataBase Reference)
EPA chemische Informationen	1-Butanone, 3-amino-1-[5,6-dihydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)-, (3R)- (486460-32-6)

Sicherheit

Giftige Stoffe Daten

486460-32-6(Hazardous Substances Data)

Gefahreninformationscode (GHS)

Sitagliptin Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung
Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, is a first-in-class oral drug launched for the treatment of type 2 diabetes. It acts by slowing the inactivation of incretins, which are endogenous peptides involved in the physiologic regulation of glucose homeostasis. Incretin hormones, including glucagonlike peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), are released by the intestine throughout the day, and levels are increased in response to a meal. When blood glucose concentrations are normal or elevated,GLP-1 and GIP increase the synthesis and release of insulin from pancreatic b cells via intracellular signaling pathways involving cAMP. GLP-1 also lowers glucagon secretion from pancreatic αcells, which leads to reduced hepatic glucose production.
Originator
Merck (US)
Verwenden
Sitagliptin is a useful pharmaceutical drug. Could be useful for treating intestinal inflammation, diabetes, pre-?diabetes, impaired glucose tolerance, hepatitis, and?/or inflammatory liver disease.
Verwenden
Labeled Sitagliptin , intended for use as an internal standard for the quantification of Sitagliptin by GC- or LC-mass spectrometry.
Definition
ChEBI: Sitagliptin is a triazolopyrazine that exhibits hypoglycemic activity. It has a role as a serine proteinase inhibitor, a hypoglycemic agent, an EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor, an environmental contaminant and a xenobiotic. It is a triazolopyrazine and a trifluorobenzene.
Trademarks
Januvia
Clinical Use
Treatment of type 2 diabetes in combination with metformin or a thiazolidinedione
Stoffwechsel
Sitagliptin undergoes minimal metabolism, mainly by the cytochrome P450 isoenzyme CYP3A4, and to a lesser extent by CYP2C8.
Renal excretion of sitagliptin involves active tubular secretion; it is a substrate for organic anion transporter-3 and P-glycoprotein.

Sitagliptin Upstream-Materialien And Downstream Produkte

Sitagliptin Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

486460-32-6, Sitagliptin Verwandte Suche:

Send Inquriy